Abacus Planning Group Inc. Invests $325,000 in DENTSPLY SIRONA Inc (NASDAQ:XRAY)

Abacus Planning Group Inc. acquired a new position in DENTSPLY SIRONA Inc (NASDAQ:XRAY) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,105 shares of the medical instruments supplier’s stock, valued at approximately $325,000.

Other institutional investors have also recently modified their holdings of the company. Altshuler Shaham Ltd lifted its stake in shares of DENTSPLY SIRONA by 209.8% in the second quarter. Altshuler Shaham Ltd now owns 505 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 342 shares during the last quarter. Quest Capital Management Inc. ADV acquired a new stake in shares of DENTSPLY SIRONA in the third quarter worth $30,000. Cornerstone Advisors Inc. lifted its stake in shares of DENTSPLY SIRONA by 62.0% in the second quarter. Cornerstone Advisors Inc. now owns 904 shares of the medical instruments supplier’s stock worth $53,000 after buying an additional 346 shares during the last quarter. Van ECK Associates Corp acquired a new stake in shares of DENTSPLY SIRONA in the second quarter worth $54,000. Finally, Arcadia Investment Management Corp MI acquired a new stake in shares of DENTSPLY SIRONA in the second quarter worth $58,000. Institutional investors and hedge funds own 93.46% of the company’s stock.

A number of analysts have recently weighed in on XRAY shares. BidaskClub cut shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research note on Tuesday, October 29th. Evercore ISI assumed coverage on shares of DENTSPLY SIRONA in a research report on Friday, July 26th. They set an “in-line” rating on the stock. Wellington Shields raised shares of DENTSPLY SIRONA from a “hold” rating to a “gradually accumulate” rating in a research report on Friday, August 2nd. Barrington Research reaffirmed a “buy” rating and set a $63.00 target price on shares of DENTSPLY SIRONA in a research report on Monday, August 5th. Finally, ValuEngine lowered shares of DENTSPLY SIRONA from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. DENTSPLY SIRONA has a consensus rating of “Hold” and a consensus target price of $55.75.

Shares of XRAY stock opened at $55.59 on Thursday. DENTSPLY SIRONA Inc has a 1 year low of $34.93 and a 1 year high of $59.40. The firm’s fifty day simple moving average is $53.59 and its 200 day simple moving average is $54.11. The firm has a market capitalization of $12.43 billion, a P/E ratio of 27.66, a price-to-earnings-growth ratio of 1.99 and a beta of 0.96. The company has a current ratio of 2.08, a quick ratio of 1.39 and a debt-to-equity ratio of 0.30.

DENTSPLY SIRONA Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Read More: Cost of Debt

Want to see what other hedge funds are holding XRAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DENTSPLY SIRONA Inc (NASDAQ:XRAY).

Institutional Ownership by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.